{"nctId":"NCT03473561","briefTitle":"Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea","startDateStruct":{"date":"2018-08-25","type":"ACTUAL"},"conditions":["Diarrhea, Infantile"],"count":31,"armGroups":[{"label":"Racecadotril plus standard treatment oral rehydration solution","type":"EXPERIMENTAL","interventionNames":["Drug: Racecadotril plus ORS"]}],"interventions":[{"name":"Racecadotril plus ORS","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent from one of the parent(s)/legal representative(s)\n* Subjects, both genders, aged 3 to 60 months\n* Subjects with acute diarrhea (defined as the passage of three or more unformed or liquid stools within the last 24 hours and lasting for less than 3 days)\n\nExclusion Criteria:\n\n* Known allergy to Racecadotril or any of its ingredients\n* Subjects suffering from renal or hepatic impairment\n* Subjects with fever \\> 39 degrees Celsius\n* Subjects with bloody and/or purulent stools\n* Subjects suffering from antibiotic (e.g. amoxicillin)-associated diarrhea, chronic diarrhea or iatrogenic diarrhea\n* Subjects with alternating bouts of diarrhea and constipation\n* Diarrhea due to exacerbation of chronic gastrointestinal diseases such as irritable bowel syndrome, irritable bowel disease or pancreatic exocrine insufficiency\n* Cystic fibrosis or coeliac disease\n* Subjects suffering from prolonged or uncontrolled vomiting\n* Subjects with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption syndrome or sucrase isomaltase insufficiency\n* Subjects having received antibiotic treatment at any time within 2 weeks prior to inclusion into the study\n* Subjects having received antidiarrheal drugs 48 hours prior to inclusion into the study\n* Subjects with severe dehydration requiring intravenous fluid, electrolyte replacement or hospitalization treatment\n* Subject with a history of angioedema or who had reported angioedema with angiotensin converting enzyme inhibitors (such as captopril, enalapril, lisinopril, perindopril, ramipril)\n* Subjects with combined diseases or medical situations that would prevent to be enrolled into the study, depending on the judgment of the investigator\n* Intake of experimental drug within 30 days prior to study start\n* Subjects with contraindications to ORS or susceptible to the warnings of ORS","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"60 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5 Days","description":"Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":"5.79"}]}]}]},{"type":"SECONDARY","title":"Number of Recovered Subjects","description":"Number of recovered subjects","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Physician Assessment at the End of Treatment","description":"Scores 1-6 (Scores 1 and 2 are defined as success)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["Upper respiratory tract infection","Diarrhoea","Laryngitis","Bronchiolitis","Dermatitis"]}}}